GSK acquires Nuvalent for $10.6 billion to boost cancer drug pipeline
British pharmaceutical giant GSK has agreed to acquire Boston-based biotech Nuvalent for $10.6 billion in cash, paying a 40% premium. The deal, GSK's largest in over a decade, adds three non-small cell lung cancer treatments (zidesamtinib, neladalkib, NVL-330) to its oncology portfolio. GSK expects revenue from 2027 to offset declining HIV drug sales and plans to cut up to 350 R&D jobs in the US and UK. The acquisition reflects a broader biotech dealmaking surge driven by patent cliffs.
Cross-source coverage
Wire timeline
Acquisition of Nuvalent Signals Positive Outlook for Nuvation Bio
On June 9, 2026, GSK agreed to acquire cancer drug developer Nuvalent for $10.6 billion, a move that analysts see as a positive sign for Nuvation Bio (NUVB). RBC Capital reiterated a Buy rating on Nuvation Bio with a $20 price target, noting that Nuvalent competes directly with Nuvation in the ROS1 non-small cell lung cancer space. GSK attributed up to $3.5 billion of the deal to Nuvalent's ROS1 asset, and management indicated it would consider acquiring a separate ROS1 inhibitor, putting Nuvation Bio in the spotlight as a potential target. Nuvation Bio reported fiscal Q1 2026 revenue of $83.2 million, exceeding estimates of $62.7 million, with IBTROZI net product revenue reaching $18.5 million, an 18% year-over-year increase. Analysts remain bullish, with a 12-month average price target suggesting roughly 150% upside from current levels.
Yahoo FinanceGSK Acquires Nuvalent for $10.6 Billion to Offset Patent Cliff Losses
GSK has agreed to acquire Nuvalent, a clinical-stage biotech firm, for $10.6 billion in an all-cash deal at $124 per share, representing a roughly 40% premium. The acquisition is driven by GSK's need to offset anticipated revenue losses from the patent expiration of its HIV drug dolutegravir, expected between 2028 and 2030. Nuvalent brings two late-stage targeted oncology assets—zidesamtinib (ROS1 inhibitor) and neladalkib (ALK inhibitor)—both with FDA Breakthrough Therapy designations and upcoming PDUFA dates in late 2026. The deal triggered a short squeeze in Nuvalent shares and may pressure competitors like Roche and Pfizer to pursue defensive acquisitions. The transaction is expected to close in Q3 2026.
Yahoo FinanceGSK boosts oncology rebuild with $11 billion Nuvalent deal
GSK announced its record $10.6 billion acquisition of U.S. biotech Nuvalent, codenamed Project Nashville, to accelerate its return to oncology. The deal brings two late-stage lung cancer treatments targeting ROS1- and ALK-positive mutations, expected to gain U.S. approval this year. The acquisition is part of CEO Luke Miels' strategy to rebuild GSK's cancer drug business after the company exited oncology in a 2015 asset swap with Novartis. Investors view the deal as correcting a strategic misstep and helping offset patent cliffs on HIV drug dolutegravir. GSK faced competition for Nuvalent, paying a 40% premium. Analysts note the drugs may not be mega-blockbusters but could achieve $3-4 billion peak sales. The deal is expected to close in Q3 2026.
Yahoo FinanceNuvalent Stock Hits All-Time High Following GSK's $10.6 Billion Buyout Offer
Nuvalent (NUVL) stock surged to an all-time high on June 9, 2026, after GSK announced a $10.6 billion all-cash acquisition. The tender offer of $124 per share represents a 40% premium over the previous close. The deal adds two near-approval lung cancer therapies, zidesamtinib and neladalkib, to GSK's portfolio, with FDA decisions expected in September and November. BofA analysts project combined peak annual sales of up to $4 billion. GSK expects the transaction to be profitable from 2027 and help offset revenue declines from its HIV drug losing exclusivity in 2028. NUVL shares now trade just below the buyout price, limiting further upside. Wall Street had a consensus 'Strong Buy' rating with a mean target of nearly $144 before the announcement.
Yahoo FinanceGSK acquires Nuvalent for $10.6 billion in oncology push
GSK announced on June 9, 2026, its agreement to acquire Boston-based clinical-stage biopharmaceutical company Nuvalent for $10.6 billion in an all-cash deal, representing a 40% premium over Nuvalent's closing share price. The acquisition, GSK's largest in over a decade, gives GSK three non-small cell lung cancer programs: zidesamtinib (ROS1 inhibitor), neladalkib (ALK inhibitor), and NVL-330 (HER2 inhibitor). FDA regulatory decisions on the two lead candidates are expected on September 18 and November 27, 2026. GSK CEO Luke Miels, who took office in early 2026, justified the large deal as purchasing three distinct products. The transaction will be funded through debt and cash, with no expected impact on GSK's credit rating. GSK expects the deal to boost revenue and core operating profit from 2027, with positive EPS impact from 2029. The companies anticipate closing the deal before the end of Q3 2026, subject to regulatory approvals including Hart-Scott-Rodino clearance.
Yahoo FinanceGSK to Buy Nuvalent for $10.6 Billion in Oncology Push
British pharmaceutical company GSK has agreed to acquire U.S. cancer-drug developer Nuvalent for $10.6 billion, marking its latest strategic move to strengthen its oncology business. The deal involves a tender offer of $124 per share in cash. The acquisition will give GSK two lung cancer drug candidates currently under review by the U.S. Food and Drug Administration, as well as a third, earlier-stage medicine. The announcement was made on June 10, 2026, and underscores GSK's efforts to rebuild its position in the competitive cancer treatment market.
Yahoo FinanceGSK to Acquire Nuvalent for $10.6 Billion, Boosting Oncology Pipeline
British pharmaceutical giant GSK has agreed to acquire U.S.-based oncology biotech Nuvalent for $10.6 billion in an all-cash deal, representing a 40% premium to Nuvalent's last closing price. The acquisition, GSK's largest in over a decade, gives the company access to two late-stage lung cancer treatments (neladalkib and zidesamtinib) with blockbuster potential, as well as an early-stage medicine and preclinical programs. The deal is strategically aimed at offsetting expected revenue declines when GSK's best-selling HIV drug loses exclusivity from 2028. Nuvalent shares surged 39% in premarket trading, while GSK shares fell 2.6% in London. The transaction marks a departure from GSK's recent focus on smaller deals and comes amid a broader biotech M&A frenzy driven by patent cliffs and buoyant markets. Barclays analysts questioned the mega-blockbuster status of the assets but noted the deal makes strategic sense. GSK maintained its 2026 full-year guidance and expects revenue growth contribution from 2027.
US Top News and AnalysisGSK boosts cancer pipeline with $11B Nuvalent buyout
GSK announced on June 9, 2026, that it will acquire Nuvalent, a Massachusetts-based biotech company, for $11 billion. The deal includes two cancer drugs under FDA review: zidesamtinib (ROS1 inhibitor, decision due Sept. 18) and neladalkib (ALK inhibitor, decision due Nov. 27). GSK plans to build a lung cancer franchise around these drugs, which target tumors with ROS1 and ALK mutations. The acquisition price is $124 per share, a 40% premium over the previous close. GSK will fund the deal through debt, expects it to be profitable from 2027, and says it will not affect its credit rating or dividend. This is GSK's largest acquisition in eight years and its third in 2026, totaling nearly $14 billion in spending.
Yahoo FinanceGSK to buy Nuvalent for US$10.6 billion to expand in cancer drugs
British pharmaceutical company GSK has agreed to acquire Nuvalent, a US-based biotech firm, in a deal valued at US$10.6 billion. GSK will pay US$124 per share for Nuvalent, marking a significant expansion of its cancer drug portfolio. The acquisition is part of GSK's strategy to grow its oncology business, which it re-entered in 2019. The deal underscores the company's commitment to strengthening its pipeline in the competitive cancer therapeutics market.
The Business TimesGSK to buy Nuvalent for US$10.6 billion to expand in cancer drugs
British pharmaceutical company GSK has agreed to acquire Nuvalent, a US-based biotech firm, in a deal valued at US$10.6 billion. GSK will pay US$124 per share for Nuvalent. The acquisition marks a significant expansion of GSK's cancer drug portfolio, which has been gradually growing since the company re-entered the oncology space in 2019. The deal underscores GSK's strategic focus on bolstering its pipeline in cancer therapeutics.
The Business TimesGSK Announces $10.6 Billion Acquisition of Nuvalent to Revive Cancer Drug Pipeline
British pharmaceutical giant GSK has agreed to acquire U.S.-listed biotech company Nuvalent for $10.6 billion, marking its largest acquisition in eight years. The deal is aimed at strengthening GSK's oncology portfolio, which the company had previously scaled back. Nuvalent specializes in developing targeted cancer therapies, and the acquisition signals GSK's renewed commitment to the cancer drug market. The transaction underscores a broader trend of major pharmaceutical firms investing heavily in oncology assets to offset patent expirations and bolster growth pipelines.
MarketWatch.com - Top StoriesGSK acquires US cancer treatment firm Nuvalent in $10.6 billion deal
British pharmaceutical giant GSK has announced a $10.6 billion deal to acquire Boston-based biopharmaceutical company Nuvalent, paying $124 per share in cash, a 40% premium over the stock's pre-announcement price. The acquisition, expected to close in the third quarter of 2026, covers three lung cancer treatment products designed to minimize side effects and overcome drug resistance. GSK anticipates revenue from these drugs starting in 2027 to offset declining sales from its HIV drug losing exclusivity, and to help achieve its target of over £40 billion in annual sales by 2031. The company also warned investors of moderating profit growth in 2026, with operating profit expected between 7-9%, and announced plans to cut up to 350 R&D jobs in the US and UK as part of a restructuring.
City AMGSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
UK pharmaceutical giant GSK is in advanced talks to acquire oncology biotech firm Nuvalent for more than $9 billion, according to the Financial Times. The deal, which could be finalized as early as this week, would be GSK's largest acquisition in over a decade and a departure from its recent focus on smaller transactions. Nuvalent's lead assets include neladalkib and zidesamtinib, both under FDA review for lung cancer treatments. Analysts estimate these drugs could generate combined annual revenues of $823 million by 2029. The acquisition comes amid a biotech dealmaking frenzy driven by patent cliffs, buoyant public markets, and pharma companies racing to bolster pipelines. Global biotech deals have reached $106 billion across 201 transactions so far in 2026.
US Top News and Analysis